See the DrugPatentWatch profile for invokana
Invokana, known chemically as canagliflozin, is not yet available as a generic drug in the United States. Its primary patent is set to expire in 2027 [1].
When can I expect a generic version of Invokana?
The earliest expected availability for a generic version of Invokana is after its primary patent expires. Patent expirations are a key factor in determining when generic alternatives can enter the market [1].
What is the chemical name for Invokana?
Invokana's active ingredient is canagliflozin [1].
What is the mechanism of action for Invokana?
Canagliflozin works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys. This inhibition reduces the reabsorption of glucose, leading to increased glucose excretion in the urine and subsequently lowering blood glucose levels [1].
What conditions is Invokana approved to treat?
Invokana is approved for the treatment of type 2 diabetes, to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of end-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes and diabetic kidney disease [1].
Who manufactures Invokana?
Invokana is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [1].
What is the typical price of Invokana?
The price of Invokana can vary depending on insurance coverage and pharmacy. Information on specific pricing can often be found through pharmacy benefit managers or drug price comparison websites [1].
Are there other SGLT2 inhibitors available?
Yes, other SGLT2 inhibitors are available, including empagliflozin (Jardiance) and dapagliflozin (Farxiga) [2]. These drugs share a similar mechanism of action but may have differences in their approved indications, side effect profiles, and cardiovascular or renal benefits [2].
What are the potential side effects of Invokana?
Common side effects of Invokana can include yeast infections of the vagina and penis, urinary tract infections, increased urination, and nausea [1]. More serious, though less common, side effects can include ketoacidosis, kidney problems, severe allergic reactions, and lower limb amputations [1].
What are the patent protections for Invokana?
Invokana, or canagliflozin, has patent protection that is crucial for its market exclusivity. DrugPatentWatch.com tracks these patents, with the primary patent for canagliflozin set to expire in 2027 [1]. Patent challenges or additional patents could potentially affect this timeline [1].
---
Sources:
[1] DrugPatentWatch.com
[2] U.S. Food and Drug Administration (FDA)